Investor relations
A platform business built on combination technology.
Our value comes from technologies that other manufacturers build into their own devices: coating science, drug-release control and the regulatory experience to carry combination products through review.
- Headquarters
- Vancouver, British Columbia
- Focus
- Specialty devices & combination pharmaceuticals
- Revenue model
- Licensing, royalties and partnered development
- Fiscal year end
- 31 December
Governance
Our board oversees programme risk, capital allocation and the quality system that every combination product depends on. Committee composition is listed with the board on our leadership page.
View leadership and board →Latest announcements
Drug-carrying closure programme advances to expanded clinical evaluation
Vancouver biomaterials laboratory expands coating characterisation capacity
Research collaboration on localised oncology delivery
Investor enquiries
Our investor relations team responds directly from Vancouver.